Efficacy of dulaglutide after switching from incretin related drugs in patients with type 2 diabetes

Efficacy of dulaglutide after switching from incretin related drugs in patients with type 2 diabetes - Efficacy of dulaglutide after switching from incretin related drugs in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042812

Enrollment

100

Registered

2020-12-22

Start date

2016-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who were administered dulaglutide over 6 months

Exclusion criteria

Exclusion criteria: Subjects in whom antidiabetic agents other than GLP-1 RAs or DPP-4 inhibitors were changed during the observation period

Design outcomes

Primary

Measure	Time frame
HbA1c and body weight at 6 months	—

Countries

Japan

Contacts

Public ContactHiroyuki Ito

Edogawa Hospital Department of Diabetes, Metabolism and Kidney Disease

ito@edogawa.or.jp03-3673-1221

Outcome results